Dyzbac and Latanoprost

• Generic Name: multivitamin
• Dosage Forms: tablet
• Other Brand Names:

  Berocca, Primaplex, GNP Antibiotic Plus Pramoxine, Multi Antibiotic Plus, Neosporin Plus Pain Relief MS, RA Antibiotic Plus, SM Antibiotic Plus Pain Relief, TGT First Aid Antibiotic, TH Antibiotic + Pain Relief, BProtected Pedia Poly-Vite, PediaVit, Polyvitamin OR SOLN, Natrol SAMe, Protegra, Vicon Forte, Stress-600, Thera-Tabs, AquADEKs, Pedia Tri-Vite Drops, Tri-Vita, Vitamax Pediatric

Dytuss is an antihistamine that reduces the effects of natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.

Dytuss is used to treat sneezing, runny nose, watery eyes, hives, skin rash, itching, and other cold or allergy symptoms.

Dytuss is also used to treat motion sickness, to induce sleep, and to treat certain symptoms of Parkinson's disease.

Dytuss may also be used for purposes not listed in this medication guide.

• Generic Name: latanoprost ophthalmic
• Dosage Forms: n.a.
• Other Brand Names: Xalatan, Xelpros, Xalatan Multi-Pack

Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. One of several first-line agents to reduce elevated IOP.

Safety and efficacy not established for the treatment of angle-closure, inflammatory, or neovascular glaucoma.

Appears to be more effective than unoprostone, as effective as travoprost, and slightly less effective than bimatoprost in reducing IOP in patients with open-angle glaucoma or ocular hypertension.

May be more effective or at least as effective as twice daily administration of timolol 0.5% in reducing IOP in patients with open-angle glaucoma or ocular hypertension. Appears to be more effective than thrice-daily administration of dorzolamide 2%.

May be used in conjunction with a topical β-adrenergic blocking agent (e.g., betaxolol, carteolol, levobunolol, metipranolol, timolol), topical dipivefrin, topical epinephrine, an oral carbonic anhydrase inhibitor (e.g., acetazolamide), or a topical carbonic anhydrase inhibitor (e.g., dorzolamide).

Tolerance does not occur, and reduction in mean IOP is maintained for up to at least 24 months of therapy after initial stabilization.